Moneycontrol Be a Pro
Get App
SENSEX NIFTY
YOU ARE HERE > MONEYCONTROL > MARKETS > Pharmaceuticals > Balance Sheet - Advanced Enzyme Technologies

Advanced Enzyme Technologies

BSE: 540025|NSE: ADVENZYMES|ISIN: INE837H01020|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Nov 20, 16:00
177.90
16.55 (10.26%)
VOLUME 50,166
LIVE
NSE
Nov 20, 15:59
178.20
16.65 (10.31%)
VOLUME 454,270
Download Annual Report PDF Format 2017 | 2016

Balance Sheet of Advanced Enzyme Technologies

------------------- in Rs. Cr. -------------------
Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
12 mths 12 mths 12 mths 12 mths 12 mths
EQUITIES AND LIABILITIES
SHAREHOLDER'S FUNDS
Equity Share Capital 22.33 22.33 22.33 21.77 21.77
Total Share Capital 22.33 22.33 22.33 21.77 21.77
Reserves and Surplus 293.62 266.57 232.90 153.08 134.40
Total Reserves and Surplus 293.62 266.57 232.90 153.08 134.40
Employees Stock Options 3.53 0.00 0.00 0.00 0.00
Total Shareholders Funds 319.47 288.90 255.23 174.85 156.17
NON-CURRENT LIABILITIES
Long Term Borrowings 1.70 7.95 12.13 15.60 5.15
Deferred Tax Liabilities [Net] 3.85 1.53 2.25 15.76 14.77
Long Term Provisions 0.51 0.56 0.70 0.18 0.00
Total Non-Current Liabilities 6.06 10.03 15.08 31.54 19.92
CURRENT LIABILITIES
Short Term Borrowings 16.51 32.33 21.13 29.45 22.38
Trade Payables 15.58 21.20 8.48 9.78 7.53
Other Current Liabilities 16.60 18.75 16.00 13.41 14.70
Short Term Provisions 1.66 1.80 1.61 2.52 1.91
Total Current Liabilities 50.36 74.08 47.22 55.17 46.51
Total Capital And Liabilities 375.89 373.00 317.53 261.55 222.59
ASSETS
NON-CURRENT ASSETS
Tangible Assets 95.02 97.61 98.24 101.23 105.72
Intangible Assets 2.33 0.27 0.14 0.05 0.01
Capital Work-In-Progress 1.26 2.43 1.50 1.84 0.24
Intangible Assets Under Development 5.74 7.88 6.55 6.20 4.95
Fixed Assets 104.35 108.18 106.42 109.32 110.92
Non-Current Investments 120.46 120.04 103.41 53.08 27.32
Long Term Loans And Advances 35.54 29.35 1.37 17.82 15.98
Other Non-Current Assets 8.54 6.44 6.07 0.13 0.04
Total Non-Current Assets 268.89 264.00 217.27 180.34 154.26
CURRENT ASSETS
Inventories 58.62 54.86 51.06 47.40 39.38
Trade Receivables 38.15 38.58 30.97 22.78 0.95
Cash And Cash Equivalents 0.54 0.48 0.60 1.54 24.42
Short Term Loans And Advances 0.02 2.06 2.07 2.84 2.86
OtherCurrentAssets 9.67 13.02 15.57 6.65 0.72
Total Current Assets 107.00 109.00 100.26 81.20 68.33
Total Assets 375.89 373.00 317.53 261.55 222.59
OTHER ADDITIONAL INFORMATION
CONTINGENT LIABILITIES, COMMITMENTS
Contingent Liabilities 30.86 30.45 26.01 19.84 0.00
CIF VALUE OF IMPORTS
Raw Materials 0.00 0.00 0.00 22.94 18.65
Stores, Spares And Loose Tools 0.00 0.00 0.00 1.78 0.70
Capital Goods 0.00 0.00 0.00 1.16 0.24
EXPENDITURE IN FOREIGN EXCHANGE
Expenditure In Foreign Currency 28.58 24.25 24.25 2.13 3.96
REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS
Dividend Remittance In Foreign Currency - - - 0.53 0.53
EARNINGS IN FOREIGN EXCHANGE
FOB Value Of Goods - 55.78 55.78 45.95 44.60
Other Earnings 66.90 - - 0.16 -
BONUS DETAILS
Bonus Equity Share Capital 15.55 15.55 15.55 15.55 15.55
NON-CURRENT INVESTMENTS
Non-Current Investments Quoted Market Value - - - - -
Non-Current Investments Unquoted Book Value 120.46 120.04 103.41 53.08 27.32
CURRENT INVESTMENTS
Current Investments Quoted Market Value - - - - -
Current Investments Unquoted Book Value - - - - -
Source : Dion Global Solutions Limited

Results of Advanced Enzyme

  • News
  • Results
  • Estimates
  • Analysis

Results of Pharmaceuticals Sector

  • News
  • Results
  • Estimates
  • Analysis
No news.
Quick Links for advancedenzymetechnologies
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.